Posted in Company - About FirstVue

Firstvue Corporation market success has come from a broad acceptance of the performance of its products by clinical laboratory professionals. All of Firstvue Corporation's products are based on the same unique membrane technology, which relies on highly specific antigen-antibody reactions allowing for the detection of disease-specific markers in clinical specimens. In our rapid tests, a special membrane is coated with disease-specific antigens or antibodies to capture the corresponding marker in the test sample, thus allowing for the detection of the disease. The simple testing procedure involves placing a drop of the test sample on the coated test membrane and allowing it to flow through the membrane. If the sample contains the target antibodies or antigens, they are captured on the test membrane and result in a highly specific antigen-antibody complex. The test result is visualized at a colored line through a reaction with a proprietary detection agent and can be interpreted immediately.

Patent Pending, Micro Flow Technology Firstvue Corporation deploys its unique micro flow-through testing platform; including a single buffer solution for preparation and performance of the test and unique colorimetric agent, which allows for a visual interpretation of test results. The testing procedure is completed within minutes. Precision pipetting, sample manipulation or specialized equipment is not required to perform any of Firstvue Corporation's rapid tests, making it an invaluable diagnostic resource in laboratories that are space and time limited.
 
Multiple Applications
Firstvue Corporations market-proven, membrane technology platform can be used quickly and efficiently to develop tests for many diseases, from smallpox to emerging diseases such as avian influenza. Firstvue Corporation  develops disease-specific rapid tests based on its proprietary technology, making all test procedures similarly simple and user-friendly. As a result, Firstvue Corporation is able to develop and market reliable, high-quality tests for other diseases quickly, and ensure ready acceptance and use by medical laboratories.

The ROS Protein Platform is Firstvue Corporation new patent pending rapid test technology. we have signed an exclusive license agreement for a first-of-its-type fluorescence technology for the retail rapid test kit marketplace, the new development is a highly sensitive immunoassay that is a breakthrough in the sensitivity limitation of rapid one-step lateral flow immunoassay. This platform retains the technical edge of conventional rapid one-step immunoassay and adds the performance of highly sophisticated and expensive instrument-reliant test systems.

Since it is 50-1000 times more sensitive than current rapid one-step assays, ROS Protein Platform will allow First Diagnostic to penetrate market segments in front of other established companies. These segments have been inaccessible by the current version of rapid assays primarily due to their limitations in sensitivity. The Companys partner has filed a patent application and expects to market ROS Protein Platform products.

The ROS Gene POCT Platform is being developed in two different formats for a more integrated, interdisciplinary approach to developing a new area of diagnostics that will have future worldwide market demand. ROS Gene POCT I is the one-step lateral flow technology that is based on PCR-based methodology for the selective amplification of DNA or RNA target sequences. With this technology, current threats such as the West Nile Virus and the Dengue Virus as well as other Flaviviruses will become possible to detect with employment of ready-to-use PCR kits and POCT devices that do not require expensive, real-time detection instruments.

ROS Gene POCT I will also set the foundation for the development of much needed sexually transmitted disease (STD) and Biological Warfare panels. ROS Gene POCT II platform will enable the detection of low concentrations of specific genomic DNA sequences from biological pathogens, potentially down to a single nucleotide, with or without an integrated PCR reaction.
 
We expect to be highly competitive in the market due to our scientists's ability to process reagents in conjunction with their expertise in producing high quality end-products in various diagnostic applications for genetic diseases, cancer prognosis, individual identifications, infectious disease identifications, and others.

Posted in Company - News

The lateral-flow point-of-care (POC) test market is expected to grow steadily and increase by more than 40% in five years. According to a report by Kalorama Information (New York City), titled “Lateral-Flow Technology and the Future of Point-of-Care Diagnostics,” the combined over-the-counter (OTC) and professional lateral-flow POC tests generated global revenues of $1.88 billion in 2005.

Read more...

Posted in Company - About FirstVue

Firstvue™ Stat-Packs One/Step Rapid Test Professional Series for Clinical Use Only:

Firstvue™ a leading brand in the field of rapid diagnostic products to laboratory and healthcare professionals in both preventative and interventional medicine.  Our products provide qualitative and quantitative analysis of patients’ body fluids or tissue, giving evidence of specific medical conditions and disease.  Our high quality immunoassays in infectious diseases, autoimmune disorders, cancer and cardiology have demonstrated proven efficiency in clinics, hospitals and laboratories around the world.
 
We are proud to offer an expanding range of professional clinical diagnostic products that includes our well known and regarded brands as Firstvue™ & inSTIvue™.  We also continually evaluate other technological advancements, for development or acquisition, in a variety of medical/health areas. On the developmental side of the business, we are exploring opportunities that will make optimum use of our new ROS Gene Platform technologies.

Markets Served

•     Hospitals, laboratories and clinics
•     Physicians office practices
•     Consumers and retail pharmacies
•     Public health agencies
•     Pharmaceutical companies
•     Healthcare workers
•     Blood banks

Please note that individual products may have different specifications in various markets.  Also, some products may not be available in all markets worldwide, only in selected markets; available for sale in over 45 countries for use by Medical Professionals, Physicians, Governments, Health Ministries, Police Departments, Clinical Laboratories, Hospitals, the home user and Retail Chain Stores. Our goal is to address solutions for the most pressing issues in healthcare today: the inability of people to obtain FAST, convenient, and confidential results about their health issues.

Firstvue™ Rapid Test Benefits:

•     Registered Medical Device
•     On-the-spot testing in both men and women
•     The ability to stem the development of health complications at an early stage
•     Prevention of unnecessary anxiety waiting for test results
•     Easily performed test results in minutes interpreted by all personnel
•     Laboratory Accuracy Colloidal Gold Technology with Built-in test controls
•     High Sensitivity & Specificity to ensure proper diagnosis
•     Uses multiple specimen types; minimizes specimen incompatibility and rejection
•     Long Shelf Life, Room Temperature Storage

Packed 20- 40 Tests to a Box, for professional use; i.e. hospital & physician offices - Register online and order at wholesale pricing right now!
 

Posted in Company - About FirstVue

Firstvue Corporation uses a FDA registered medical device company Registration Number: 3007009966 Owner Operator Number: 10026251. Using quality systems are certified to ISO 13485:2003 standards That are compliant with QSR (cGMP). Manufacturing and in-line packaging meet or exceed the rigorous regulatory demands of today's global marketplace.
 
Firstvue Corporation directs all operations at our selected Contract Manufacturing site.  The Contract Manufacture's are ISO 13485 certified, cGMP compliant and ROHS compliant. The manufacturing operation is designed to be scalable from low volume prototyping to high volume production.

Firstvue Corporation Rapid Field Tests are used in over 40 countries including; Africa, Malaysia, Canada, United States, Germany, Belgium, Spain, Turkey, Australia, Hong Kong, Korea, Africa, Mexico, Middle East...
 
Pregnancy (hCG) Rapid Strips(Urine)
Ovulation (LH) Rapid Strips (Urine)
FSH Menopausal Test Strips (Urine)
HBsAb One Step Hepatitis B Surface Antibody Strips  (Serum/Plasma)
HBsAb Rapid Hepatitis B Surface Antibody Strips  (Whole Blood/Serum/Plasma)
HBsAg One Step Hepatitis B Surface Antigen Strips  (Serum/Plasma)
HBsAg Rapid Hepatitis B Surface Antigen Strips  (Whole Blood/Serum/Plasma)
HBeAb One Step Heptitis B Envelope Antibody Strips  (Serum/Plasma)
HBeAg One Step Heptitis B Envelope Antigen Strips  (Serum/Plasma)
HCV Rapid Hepatitis C Virus Strips  (Serum/Plasma)
HCV Rapid Hepatitis C Virus Strips  (Whole Blood/Serum/Plasma)
HIV Rapid Strips  (Serum/Plasma)
HIV Rapid Strips  (Whole Blood/Serum/Plasma)
HIV 1/2/O Tri-line Rapid Strips  (Whole Blood/Serum/Plasma)
H. pylori Rapid Strips  (Whole Blood/Serum/Plasma)
Malaria P.f. Rapid Strips  (Whole Blood)
MONO Mononucleosis Rapid Strips  (Whole Blood/Serum/Plasma)
Strep A Rapid Strips  (Throat Swab)
Syphilis One Step Strips  (Serum/Plasma)
Rubella Rapid  Antibody (IgG/IgM) Strips (Whole Blood/Serum/Plasma)
Lyme Rapid  Antibody (IgG) Strips  (Whole Blood/Serum/Plasma)
Dengue virus IgG and IgM Strips (Whole Blood/Serum/Plasma)
Salmonella typhi IgG/IgM Strips (Whole Blood/Serum/Plasma)
TB Tuberculosis Test  (Whole Blood/Serum/Plasma)

Strip Format: (Bulk) is the Preferred method for in field testing centers. The Strip format is a One-Step dipstick test designed for clinical and professional use in the field. To use the strip, simply immerse one end of the test strip into the specimen, leave the strip in the specimen for 3 seconds, and lay the strip flat on a clean, dry, non-absorbent surface. Results appear within minutes as either single or double bands. The Strip format is a fast, accurate, very cost-effective and easy-to-use.

Bulk Strips Packaging: 24 x 18 x 18 carton contains:
10,000 pcs - strips (bulk)
 2,000 pcs  2,5000pcs cassettes (retail)
 1,600 pcs - midstream wands (bulk)

Container Loads:
Bulk, 20 ft, 240 cartons, est. 400,000  550,000 units
Bulk, 40 ft, 500 cartons, est. 800,000 - 1.1 million units
Clinic, 20 ft, 1,150 cartons, est. 30,000 units
Clinic, 40 ft, 2,600 cartons, est. 65,000 units
Retail, 20 ft, 575 cartons, est. 23,000
Retail, 40 ft, 1,300 cartons, est. 52,000

For information on how to get products in your country please contact our marketing office at This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Firstvue Corporation manufactures Infectious Disease Antigen & Antibody Detection Tests. These market-proven, flow-through membrane technology platforms can be used quickly and efficiently to develop tests for many diseases such as of HIV 1 HIV2, Hepatitis B, Hepatitis C, H. pylori, Malaria, Strep A, Mononucleosis, T.B Tuberculosis, Dengue IgG IgM, etc...

Our tests Are Ready for Sale to Government Agency;s and Health Ministries. We gladly accept Government Purchase Orders! We actively serves local, state and federal as well as governments in 50 countries worldwide with purchasers as a woman owned small business.

Over the past 8 years we have provided our products to most branches of the government. In addition, we have many state and local agencies as long term customers. We are committed to helping our government customers find the health care solutions that best meets their needs. Please email us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it for a government contract quotation or additional information about our sales programs.